口服与静脉给药氨甲环酸在择期全髋关节置换术中的疗效与安全性:随机对照试验的系统综述与Meta分析
该系统综述与Meta分析纳入9项随机对照试验共1060例择期全髋关节置换术患者,比较口服与静脉氨甲环酸。结果显示两组总失血量、输血率、住院时长及术后并发症无显著差异,口服组治疗费用更低。
要点
- 口服与静脉氨甲环酸在择期全髋关节置换术中总失血量无显著差异(均差-3.04,95%CI -39.54至33.47,P=0.97)。
- 两组输血率(OR 1.04,95%CI 0.54至1.99,P=0.92)、住院时长及术后并发症无显著差异。
- 口服氨甲环酸治疗费用低于静脉给药。
核心结论
- 择期全髋关节置换术患者中,口服氨甲环酸与静脉给药临床结果相似,但治疗费用更低。
研究设计与样本
- 系统综述与Meta分析,遵循PRISMA 2020指南并在PROSPERO注册,检索多个文献数据库的随机对照试验,纳入9项随机对照试验共1060例患者。
主要发现
- 总失血量两组无显著差异(均差-3.04,95%CI -39.54至33.47,P=0.97)。
- 输血率两组无显著差异(OR 1.04,95%CI 0.54至1.99,P=0.92)。
- 住院时长两组无显著差异(均差0,95%CI -0.03至0.03,P=0.89)。
- 术后并发症两组无显著差异。
- 口服氨甲环酸与较低治疗费用相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Oral tranexamic acid (TXA) is proposed as an alternative to intravenous (IV) use to reduce blood loss in total hip arthroplasty (THA). However, its cost-effectiveness and safety remain uncertain. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of oral versus IV prophylactic administration of TXA among patients undergoing elective THA. METHODS: This systematic review and meta-analysis followed the Preferred Reporting Items for Systematic reviews and Meta-Analyses 2020 guidelines and was registered in The International Prospective Register of Systematic Reviews database. We searched several bibliographic databases for randomized controlled trials comparing oral to IV TXA administration in patients undergoing THA. Primary outcomes included intraoperative blood loss, while secondary outcomes covered transfusion rates, length of hospital stay, postoperative complications within 30 days (thromboembolic events, infections, hospital readmission), and treatment cost. RESULTS: There were nine randomized controlled trials involving 1,060 patients included. Meta-analysis revealed that there were no significant differences between the total blood loss groups (mean difference = -3.04, 95% confidence interval (CI) (-39.54 to 33.47), P = 0.97). Furthermore, there were no significant differences in transfusion rates (odds ratio = 1.04, 95% CI (0.54 to 1.99), P = 0.92), length of hospital stays (mean difference = 0, 95% CI (-0.03 to 0.03), P = 0.89), and postoperative complications. However, oral TXA was associated with a lower cost. In the subgroup analysis, we found a higher reduction in hemoglobin in the oral TXA group for multiple doses. CONCLUSIONS: Our findings suggest that in patients undergoing THA, oral administration of TXA, compared to IV administration, has similar clinical results, but with lower treatment costs.
引用
- Daghmouri MA, Salmeron F, Lahdheri AA, et al. Efficacy and Safety of Oral versus Intravenous Administration of Tranexamic Acid in Elective Total Hip Arthroplasty: A Systematic Review and Meta-Analyses of Randomized Controlled Trials. J Arthroplasty. 2025. PMID: 40306560. doi:10.1016/j.arth.2025.04.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。